Pharmaceutical glass manufacturer Schott has delivered enough of its glass vials to provide more than one billion doses of Covid-19 vaccines.
The company says it remains well on track to deliver vials for more than two billion vaccine doses throughout 2021.
The vials were delivered to projects around the world, with a focus on the US, Europe, and China. Approximately 90% of approved vaccines rely on Schott vials.
“The reaction of the pharmaceutical community to Covid-19 is a testament to the power of scientific progress,” said Dr. Frank Heinricht, CEO of Schott.
“In just under a year, all previous records for vaccine development have been shattered by not just one, but several research groups.
“The entire industry is successfully working together to ensure an adequate supply. We’re also working with our government partners to evaluate ways to improve the supply chain and expand production capacity.”
Schott is one of the world’s leading producers of pharmaceutical containers made from borosilicate glass.
The success of the Covid-19 response is supported by the company’s multi-year, $1 billion global investment in pharmaceutical glass and packaging facilities announced early 2019 in response to rising worldwide demand for safer drug packaging.
Despite the pandemic, Schott says all expansion projects are on track.
